Expert Ratings For Rhythm Pharmaceuticals
Analysts have provided the following ratings for Rhythm Pharmaceuticals (NASDAQ:RYTM) within the last quarter:
Thinking About Buying Stock In Lucid Group, Rhythm Pharmaceuticals Or Kohl’s?
Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders.
Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends.
A Preview Of Rhythm Pharmaceuticals’s Earnings
Rhythm Pharmaceuticals (NASDAQ:RYTM) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement.
Analysts estimate that Rhythm Pharmaceuticals will report an earnings per share (EPS) of $-0.91.
Why Rhythm Pharmaceuticals Shares Are Falling Today
The FDA has extended the review period for Rhythm Pharmaceuticals Inc’s (NASDAQ:RYTM) supplemental marketing application for Imcivree (setmelanotide) for obesity and control…
60 Biggest Movers From Yesterday
Gainers
Inspirato Incorporated (NASDAQ: ISPO) shares climbed 618.2% to close at $92.65 on Thursday, just a few days after the company completed its SPAC merger with Thayer Ventures.
Ladenburg Thalmann Upgrades Rhythm Pharmaceuticals to Buy, Announces $15 Price Target
Ladenburg Thalmann analyst Michael Higgins upgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) from Neutral to Buy and announces $15 price target.
Rhythm Pharmaceuticals Q3 EPS $(0.70) Beats $(0.81) Estimate
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.81) by 13.58 percent. This is a 9.09 percent increase over losses of $(0.77) per share